Forbes China officially announced the 2025 Forbes China Pioneer Innovators in Industry Development list, with Jiao Peng, Chairman and CEO of Bibo Pharma, securing a distinguished position for his exceptional contributions to the CDMO (Contract Development and Manufacturing Organization) selection.
Dr. Jiao Peng said after winning the award, “I feel greatly honored to receive this award. Looking back on our entrepreneurial journey, we’ve always stuck to our original intentions, committed to doing what’s difficult but right. By producing on an ultra-large scale of 30,000 liters, we’ve cut the cost to $10 per gram, making good medicine accessible and affordable for ordinary people. With a CAN-DO spirit, we’ve faced challenges head-on. Relying on our technical strengths and strict GMP production standards, we’ve always been customer-centric, providing high-quality services for CDMO clients and reaching more patients.”
Under Dr. Jiao’s guidance, Bibo Pharma has emerged as a frontrunner in technological breakthroughs and a model for industry progress. Its large – scale manufacturing strategy has reduced costs, expanding access to high – tier therapeutics for patients worldwide. At the same time, the company’s strict adherence to GMP standards has set new quality benchmarks in the CDMO field.
This honor not only acknowledges Dr. Jiao’s personal accomplishments but also applauds the collective efforts of the entire Bibo Pharma team. Going forward, Bibo Pharma will keep boosting R&D input and speeding up the application of advanced technologies, thereby further enhancing its contribution to better global healthcare.
